A — Agilent Technologies, Inc.

Summary of Agilent Technologies Inc. Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Revenue: $1.8 billion, a 4.4% increase on a core basis, and 7% reported growth.
• Operating Margin: 24.6%, consistent with expectations but down 50 basis points year-over-year due to tariff expenses.
• Earnings Per Share (EPS): $1.36, reflecting a 4% year-over-year growth; adjusted for weather impacts, results would have exceeded guidance.
• Gross Margin: 53.7%, down 100 basis points year-over-year, mainly due to tariffs.
• Operating Cash Flow: $268 million, with $93 million in capital expenditures and $152 million in share repurchases.
• Guidance for FY 2026: Revenue expected between $7.3 billion and $7.5 billion, maintaining core growth guidance of 4% to 6%. EPS guidance adjusted to $5.90 - $6.04.

2. Strategic Updates and Business Highlights

• Customer Intimacy: Agilent emphasized its differentiated service organization, which has secured significant wins with major pharmaceutical companies, enhancing long-term relationships and revenue potential.
• Product Innovations: Successful launches include the Altura ultra-inert column portfolio and Pro iQ LC/MS, both receiving positive customer feedback and driving growth.
• Ignite Operating System: This initiative is aimed at improving operational efficiency and decision-making, contributing to margin expansion and effective integration of acquisitions, such as BIOVECTRA.
• Market Performance: Strong growth in pharma (7%), particularly in biotech (double-digit growth), and advanced materials (20% growth) driven by semiconductor reshoring.

3. Forward Guidance and Outlook

• Q2 2026 Expectations: Revenue projected between $1.79 billion and $1.82 billion, with core growth of approximately 4% to 5.5%. EPS expected between $1.39 and $1.42, indicating a 6% to 8% growth at the midpoint.
• Full-Year Outlook: Agilent maintains its core growth range of 4% to 6%, with anticipated improvements in operating margins as tariff impacts are mitigated.

4. Bad News, Challenges, or Points of Concern

• Weather Impact: A winter storm in late January resulted in a $10 million revenue hit, primarily affecting logistics and service operations, although most of this revenue has been recovered.
• Softness in Academia and Government: The LDG segment saw lower-than-expected growth due to reduced spending in these areas, impacting cell analysis and genomics.
• Tariff Headwinds: Continued tariff pressures are expected to affect margins, although the company is confident in mitigating these through pricing and operational efficiencies.
• Geographic Disparities: Growth in the Americas was sluggish (1%) compared to stronger performance in Asia (6% growth) and Europe (4% growth), indicating regional challenges.

5. Notable Q&A Insights

• Catch-Up from Weather Impact: Most of the $10 million revenue loss from the storm is expected to be recouped in Q2.
• Margin Improvement: Guidance anticipates a 50 basis point improvement in Q2 margins, driven by pricing and volume leverage, with expectations for further improvement in the second half of the year.
• M&A Strategy: Agilent remains open to acquisitions but emphasizes a disciplined approach, focusing on strategic fit and integration capabilities enhanced by the Ignite Operating System.
• Biotech Sector: While there are signs of improved funding in the biotech sector, Agilent has yet to see a significant uptick in spending from small and mid-cap biotechs, which could impact future growth.

Overall, Agilent Technologies demonstrated resilience in Q1 2026, navigating challenges while positioning itself for continued growth through strategic initiatives and product innovations.